此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Ultra-high-performance Positron Emission Tomography (PET) of Synaptic Density, Reactive Astrogliosis and Tau in Alzheimer's Disease

2026年11月16日 更新者:Universitaire Ziekenhuizen KU Leuven

Prospective in Vivo Ultra-high-performance PET Imaging of Synaptic Density, Reactive Astrogliosis and Tau Accumulation in Alzheimer's Disease, Healthy Controls and Centenarians and Relationship With Fluid Biomarkers

AIM: to investigate the relationship between synaptic density, tau and reactive astrogliosis in Alzheimer's disease (AD) versus healthy controls and centenarians.

DESIGN: this cross-sectional study will recruit patients with biomarker-proven AD, age- and sex-matched healthy controls as well as centenarians. All subjects will undergo a neuropsychological evaluation and ultra-high-performance PET imaging sessions with 18F-SynVesT-1 (synaptic density), 18F-MK6240 (tau) and 18F-SMBT-1 (reactive astrogliosis) as well as structural and diffusion MRI. Blood samples will be taken for the evaluation of blood-based biomarkers.

研究概览

研究类型

观察性的

注册 (估计的)

70

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Vlaams-Brabant
      • Leuven、Vlaams-Brabant、比利时、3000

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

是的

有资格学习的性别

全部

取样方法

非概率样本

研究人群

Patients with Alzheimer's disease will be recruited from the memory clinic of the University Hospitals Leuven (UZ Leuven). Centenarians will be recruited from the 100-plus study at UMC Amsterdam. Healthy controls will be recruited through internet advertisements.

描述

- Patients with Alzheimer's disease (AD)

Inclusion Criteria:

  • Patient has a clinical diagnosis of biomarker proven AD (prodromal AD or dementia due to AD).
  • Patient has an mini-mental state examination (MMSE) score of 15 or higher.
  • Patient or legal representative is able to understand the patient information brochure and give written informed consent.

Exclusion Criteria:

  • Patient has a history of any major other disease that may interfere with the investigations or make the subject unfit for participation according to the interpretation by the investigator.
  • Patient is on anti-amyloid therapy.
  • Patient has contra indications for magnetic resonance imaging (MRI).
  • Patient is a current smoker.
  • Patient is currently a user (including ''recreational use'') of any illicit drugs, including cannabis, or has a history of drug or alcohol abuse.

Healthy control participants

Inclusion Criteria:

  • Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures
  • Participant is judged to be in good health by the investigator on the basis of medical history, physical examination including vital signs, clinical laboratory test and urinalysis.
  • No history or evidence of current major neurological, internal or psychiatric disorder, based on the medical assessment as described hereabove and neuropsychological assessment (Geriatric depression scale (GDS) and Beck's depression inventory (BDI)).
  • A normal structural MRI scan with respect to the participant's age as assessed by expert radiologist.
  • Participant has to be at least 40 years old

Exclusion Criteria:

  • Participant has a history of any major disease that may interfere with the investigations or make the subject unfit for participation according to the interpretation by the investigator (especially diabetes mellitus, heart disease, liver and kidney disease, or most forms of cancer).
  • Participant is a smoker or has a recent history of smoking.
  • Participant has a history or evidence of psychiatric disease.
  • Participant is currently a user (including ''recreational use'') of any illicit drugs, including cannabis, or has a history of drug or alcohol abuse.
  • Participant has a contra-indication for MRI scanning.
  • Participant suffers from claustrophobia or cannot tolerate confinement during PET-MRI scanning procedures. Subject cannot lie still for at least 30 minutes inside a scanner.
  • Participant does not understand the study procedures.
  • Participant is unwilling or unable to perform all of the study procedures or is considered unsuitable in any way by the principal investigator.
  • Participant is pregnant or is breastfeeding.

Centenarians

Inclusion Criteria:

  • Participant is included in the 100-plus study at Amsterdam UMC.
  • Participant or legal representative is able to understand the information brochure and give written informed consent.

Exclusion Criteria:

  • Participant has a history of any major disease that may interfere with the investigations or make the subject unfit for participation according to the interpretation by the investigator (especially diabetes mellitus, heart disease, liver and kidney disease, or most forms of cancer).
  • Participant is a current smoker.
  • Participant is currently a user (including ''recreational use'') of any illicit drugs, including cannabis, or has a history of drug or alcohol abuse.
  • Participant has contra indications for MRI or cannot lie still in the scanner for 30 minutes.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:CASE_CONTROL
  • 时间观点:PROSPECTIVE

队列和干预

团体/队列
干预/治疗
健康对照参与者

Ultra-high-performance positron emission tomography (PET) of monoamine oxidase B (MAO-B) using the radioligand 18F-SMBT-1 on the NeuroEXPLORER PET scanner.

Ultra-high-performance positron emission tomography (PET) of synaptic vesicle glycoprotein 2A (SV2A, synaptic density) using the radioligand 18F-SynVesT-1 on the NeuroEXPLORER PET scanner.

Ultra-high-performance positron emission tomography (PET) of tau neurofibrillary tangles using the radioligand 18F-MK6240 on the NeuroEXPLORER PET scanner.

Patients with AD

Ultra-high-performance positron emission tomography (PET) of monoamine oxidase B (MAO-B) using the radioligand 18F-SMBT-1 on the NeuroEXPLORER PET scanner.

Ultra-high-performance positron emission tomography (PET) of synaptic vesicle glycoprotein 2A (SV2A, synaptic density) using the radioligand 18F-SynVesT-1 on the NeuroEXPLORER PET scanner.

Ultra-high-performance positron emission tomography (PET) of tau neurofibrillary tangles using the radioligand 18F-MK6240 on the NeuroEXPLORER PET scanner.

Centenarians

Ultra-high-performance positron emission tomography (PET) of monoamine oxidase B (MAO-B) using the radioligand 18F-SMBT-1 on the NeuroEXPLORER PET scanner.

Ultra-high-performance positron emission tomography (PET) of synaptic vesicle glycoprotein 2A (SV2A, synaptic density) using the radioligand 18F-SynVesT-1 on the NeuroEXPLORER PET scanner.

Ultra-high-performance positron emission tomography (PET) of tau neurofibrillary tangles using the radioligand 18F-MK6240 on the NeuroEXPLORER PET scanner.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
The correlation between tau, synaptic density and reactive astrogliosis
大体时间:Baseline

Mediation and correlation analyses will be performed to investigate the correlation between tau, synaptic density and reactive astrogliosis PET measures as quantified by standardized uptake value ratios (SUVR).

Baseline
Changes in synaptic density, tau and reactive astrolgiosis between AD patients, controls and centenarians
大体时间:Baseline

Synaptic density, tau and reactive astrolgiosis PET measures, as quantified by standardized uptake value ratios (SUVR), will be compared across the three different groups: patients with AD, healthy control participants and centenarians.

Baseline

次要结果测量

结果测量
措施说明
大体时间
Correlation of synaptic density, tau and reactive astrogliosis with diffusion MRI
大体时间:Baseline

The correlation of synaptic density, tau and reactive astrolgiosis PET, as quantified by standardized uptake value ratios (SUVR) in typical regions, with diffusion MRI metrics (fibre density and fibre cross-section) in the connecting white matter bundles will be assessed.

Baseline
Correlation of synaptic density, tau and reactive astrogliosis with blood-based biomarkers
大体时间:Baseline

The correlation of synaptic density, tau and reactive astrogliosis PET measures, as quantified by standardized uptake value ratios (SUVR), with blood-based markers of synaptic integrity and reactive astrogliosis will be assessed.

Baseline
Correlation of synaptic density, tau and reactive astrogliosis with cognitive performance
大体时间:Baseline

The correlation of synaptic density, tau and reactive astrolgiosis PET measures, as quantified by standardized uptake value ratios (SUVR), with neuropsychological test scores will be assessed.

Baseline

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年12月1日

初级完成 (估计的)

2029年6月1日

研究完成 (估计的)

2029年6月1日

研究注册日期

首次提交

2026年10月8日

首先提交符合 QC 标准的

2026年10月22日

首次发布 (实际的)

2026年10月30日

研究记录更新

最后更新发布 (实际的)

2026年11月17日

上次提交的符合 QC 标准的更新

2026年11月16日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅